Analyst Price Targets — CBUS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 23, 2024 11:16 am | Austin Moeller | Canaccord Genuity | $10.50 | $3.82 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Cibus (CBUS) |
| July 29, 2024 7:32 am | Matthew Venezia | Industrial Alliance Securities | $12.50 | $4.93 | TheFly | Cibus initiated with a Buy at Alliance Global Partners |
| July 19, 2024 7:27 am | Austin Moeller | Canaccord Genuity | $11.00 | $4.80 | TheFly | Cibus assumed with a Buy at Canaccord |
Latest News for CBUS
Cibus, Inc. (CBUS) Q4 2025 Earnings Call Transcript
Cibus (CBUS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.87 per share a year ago.
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced its financial results for the quarter ended December 31, 2025, and provided a business update. Management will host a conference call and webcast today at 4:30 p.m. ET.
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report fourth quarter 2025 financial results on Tuesday, March 17, 2026. Cibus' management team will host a conference call and audio webcast at 4:30 p.m.
Cibus to utilize proprietary Rapid Trait Development System™ to enable development of durable resistance to Light Leaf Spot disease, which has caused estimated yield losses of up to £300m in recent years
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CBUS.
U.S. House Trading
No House trades found for CBUS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.